zraviv06 | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

About:

Website
Details

Posts by :

June 2, 2013 Akt inhibition for cancer treatment, where do we stand today?
June 1, 2013 FDA approved two drugs and a companion diagnostic test for the treatment of advanced or unresectable cutaneous melanoma patients
May 22, 2013 Soft Tissue Sarcoma: an Overview
May 9, 2013 The Development of siRNA-Based Therapies for Cancer
April 23, 2013 Whole exome somatic mutations analysis of malignant melanoma contributes to the development of personalized cancer therapy for this disease
April 6, 2013 Targeting Mitochondrial-bound Hexokinase for Cancer Therapy
March 25, 2013 Cancer Screening at Sourasky Medical Center Cancer Prevention Center in Tel-Aviv
March 16, 2013 A P(hD)aradox
March 7, 2013 The Importance of Cancer Prevention Programs: New Percpectives for Fighting Cancer

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,062 other followers

Email Address:
Recent Posts
- Inhibitory CD161 receptor recognized as a potential immunotherapy target in glioma-infiltrating T cells by single-cell analysis February 20, 2021
- First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer February 19, 2021
- Contribution of Nervous System Functional Deterioration to late-life Mortality: The Role Neurofilament light chain (NfL) a Blood Biomarker for the Progression of Neurological Diseases and its Correlation to Age and Life Expectancy February 19, 2021
- COVID-19-vaccine rollout risks and challenges February 17, 2021
- Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis February 15, 2021
- NLP Techniques based on NLP Year in Review — 2019 February 13, 2021
- Podcast Episodes by THE EUROPEAN VC February 12, 2021
- Need for Global Response to SARS-CoV-2 Viral Variants February 12, 2021
- New approaches to cancer therapy using mathematics February 12, 2021
- Comparing COVID-19 Vaccine Schedule Combinations, or “Com-COV” – First-of-its-Kind Study will explore the Impact of using eight different Combinations of Doses and Dosing Intervals for Different COVID-19 Vaccines February 8, 2021
Archives
Archives
Categories
Categories
Meta